EPIDEMIOLOGY OF HTLV-III IN INTRAVENOUS DRUG ABUSERS

这项建议是对HTLV-III感染的流行病学研究 年静脉注射吸毒者(IVDA)人群中 治疗。这项研究建议： (1)计算人群中HTLV-III抗体的流行率 接受治疗的IVDAS人群。 (2)建立在治疗中处于高危状态的静脉注射毒品的概况 HTLV-III的风险， (3)计算人群血清转阴率。 静脉注射在治疗中， (4)识别与静脉注射毒品有关的危险行为 感染上了 HTLV-III，以及 (5)评估筛查的影响(血清阳性或 血清阴性)对静脉注射吸毒者随后的危险行为有影响。 本研究设计为一项前瞻性队列调查 治疗中静脉滴注患者中HTLV-LII抗体的检测在这个队列中， 将进行嵌套病例对照研究，病例为突发事件 HTLV-III血清阳性个体和对照血清阴性 静脉注射用药。 有四个阶段：1.一群服用药物的静脉注射用药者 将登记治疗计划，筛查HTLV抗体- 并就相关危险因素进行了约谈。这些数据将 进行分析以确定HTLV-III抗体的流行率和 建立高风险的个人资料 基线检测为阴性的静脉注射用药将进入阶段 2每隔6天进行一次血清转换重复检测 3个月(最长3年)，以确定以下人员的比例 变得血清阳性，以及识别个人 病例对照研究。 在第三阶段，每个在初始阶段后血清阳性的IVDA 筛选将进入病例对照研究，旨在 确定HTLV-III阳性的风险因素。作为血清事件 确定病例，将选择血清阴性对照，并 (盲目地)采访。标准的流行病学程序将是 用来分析这些数据。 第四阶段是对150名血清抗体阳性患者的随访。 基线和150个血清阴性IVDA以确定如何了解 在治疗期间筛查呈阳性改变药物使用和 依维达斯离开治疗后的其他行为。

This proposal is an epidemiologic study of HTLV-III infection within a population of intravenous drug abusers (IVDAs) in treatment. This study proposes: (1) to calculate the prevalence of antibody to HTLV-III among a population of IVDAS in treatment. (2) to establish the profile of IVDAs in treatment who are at high risk for HTLV-III, (3) to calculate the incidence rate of seroconversion among the IVDAs in treatment, (4) to identify risk behaviors that are associated with IVDAs becoming infected with HTLV-III, and (5) to assess the impact that being screened (seropositive or seronegative) has upon subsequent risk behaviors of IVDAs. This study designed as a prospective cohort investigation of antibody to HTLV-lII among IVDAs in treatment. Within this cohort, a nested case-control study will be conducted, cases being incident HTLV-III seropositive individuals and controls being seronegative IVDAs. There are four phases: 1. a cohort of IVDAs who are in a drug treatment program will be enrolled, screened for antibody to HTLV- III, and interviewed about relevant risk factors. These data will be analyzed to determine the prevalence of antibody to HTLV-III and to develop a profile of high risk IVDAs who test seronegative at baseline will be entered into phase 2 repeat testing for seroconversion will be performed every 6 months (for a period up to 3 years) to determine the proportion who become seropositive, as well as to identify individuals for the case-control study. In phase 3, each IVDA who becomes seropositive after the initial screen will be entered into a case control study designed to identify risk factors for HTLV-III positivity. As seroincident cases are identified, seronegative controls will be selected and interviewed (blindly). Standard epidemiologic procedures will be employed to analyze these data. Phase 4 is a follow-up of 150 individuals who were seroprevalent at baseline and 150 seronegative IVDAs to determine how knowledge of being screened positive while in treatment changes drug use and other behavior after IvDAs leave treatment.